A study of the use of medication treatments in the US for patients with chronic, refractory, or refractable inflammatory bowel disease has found that there are fewer effective treatments than previously believed.
The research is published in the Journal of Gastroenterology & Hepatology, the journal of the American Gastrointestinal Association.
The study, published in Gastroentesthetol Hepatol, compared the use and effectiveness of a number of different treatments.
One was metrolino-insulin, an insulin-like peptide drug.
Other treatments included anti-tumor drugs, antineoplastons, anti-inflammatory drugs, and anti-carcinogens.
The authors said the results of the study “challenge the view that the development of effective treatments for inflammatory bowel diseases requires a combination of conventional and novel therapeutic approaches.”
These treatments are not only important to treat the underlying causes of the disease, but also to increase the chances of the patient’s recovery and improve the quality of life,” the authors wrote.
The authors also noted that the results “do not imply that the new therapies have a cure-all for inflammatory diseases.
We suggest that, with time, new treatments could be developed to address the underlying cause of the illness, rather than treating the symptoms and preventing its recurrence.
“A number of researchers have studied the use or efficacy of different treatment approaches for inflammatory disorders.
One of the first studies was done in the late 1980s, with researchers comparing different treatments for ulcerative colitis (UC).
The research concluded that the use was the best, but the authors suggested it could be better to focus on “the treatment of the underlying disease, rather then on a combination or adjunctive therapy” of the drugs.
A study published in 2013 in the journal Gastroencephalography found that the risk of UC patients developing Crohn’s disease had decreased over the last 20 years, and a more recent study looked at the effectiveness of different therapies for Crohns disease.